ERASE_Evaluation of early treatment response of soft tissue sarcomas under neoadjuvant hyperthermia and chemotherapy using functional MRI as well as FDG PET-CT
Recruiting
- Conditions
- Bone and articular cartilage, unspecifiedMalignant neoplasm of bone and articular cartilage of other and unspecified sitesC41.9C41
- Registration Number
- DRKS00016070
- Lead Sponsor
- Klinikum der Universität München, Campus Großhadern
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Soft tissue sarcoma of the extremities in tumor stage AJCC III with indication for neoadjuvant combined chemotherapy/hyperthermia
- Tumor board decision for treatment chemotherapy/hyperthermia
- Indication for MRI and PET-CT examinations as part of clinical care for soft tissue sarcoma
- > 18 years male/female
- GFR value >30ml/min
- Signed declaration of consent
Exclusion Criteria
- Contraindications to MRI examination, especially implants not suitable for MR, tattoos or piercings, pronounced claustrophobia
- Lack of consent and/or lack of ability to consent to the study
- Pregnancy
- Known allergy to MR contrast agent or PET-CT tracer
- GFR < 30 ml/min with renal insufficiency
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of tumor response during neoadjuvant chemotherapy/thermotherapy using dynamic contrast-enhanced as well as diffusion-weighted MRI.
- Secondary Outcome Measures
Name Time Method 1. prediction of progression-free survival using DCE-MRI and DWI.<br>2. comparison and correlation of DCE-MRI and DWI to PET-CT.